A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, TripleNegative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica 1
Drug: ARM 1: MK2870 + Pembrolizumab e Carboplatin/Paclitaxel/Pembrolizumab
ARM 2: Carboplatin/Paclitaxel/Pembrolizumab + Adriamycin/Cyclophosphamide e Pembrolizumab
Pathologies: Breast cancer
ClinicalTrials.gov: Read more about clinical trials
A Phase 3, multicenter, interventional, randomized, 1:1, open-label clinical trial conducted in patients with advanced or metastatic breast cancer, particularly triple-negative or HR+/HER2-, previously treated with standard therapies. The study includes a neoadjuvant phase in which patients receive pembrolizumab in combination with sequential chemotherapy: initially with paclitaxel + SAC – TMT or pembrolizumab + paclitaxel + carboplatin, followed by pembrolizumab + paclitaxel + carboplatin or pembrolizumab + doxorubicin and cyclophosphamide. Patients then undergo an adjuvant phase with pembrolizumab monotherapy, with the aim of improving the pathological complete response rate and event-free survival.
Last update: 12/05/2026